Aytu BioPharma, Inc. (AYTU) financial statements and ratios from SEC XBRL: revenue $66.38M (TTM), net margin -20.4%, revenue growth -32.7% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $66.38M |
| Net Margin | -20.4% |
| Revenue Growth (YoY) | -32.7% |
| EPS Growth (YoY) | -181.5% |
| FCF Growth (YoY) | -76.9% |
| Price / Book | 0.71 |
| Price / Sales | 0.42 |
| FCF Yield | -14.6% |
| Altman Z-Score | -3.15 (distress) |
| Piotroski F-Score | 5/9 |
| Sector P/E (Healthcare) | 21.7 |
AYTU overview · AYTU earnings · AYTU KPIs · AYTU investor relations · AYTU ownership · AYTU peers · AYTU filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.